Pre-Made Lepunafusp Alfa Biosimilar, Fusion Protein targeting TFRC fused with human IDUA (iduronidase, alpha-L-) isoform 1 via a peptidyl linker: Recombinant therapeutic protein targeting CD71/IMD46/T9/TFR/TFR1/TR/TRFR/p90 for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-INN-888
Pre-Made Lepunafusp Alfa Biosimilar, Fusion Protein targeting TFRC fused with human IDUA (iduronidase, alpha-L-) isoform 1 via a peptidyl linker: Recombinant therapeutic protein targeting CD71/IMD46/T9/TFR/TFR1/TR/TRFR/p90 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Lepunafusp alfa is a blood-brain-barrier-penetrating form of recombinant human alpha-L-iduronidase fused to the alpha-L-iduronidase anti-transferrin receptor antibody Fab as pabinafusp alfa. Human alpha-L-iduronidase deficiency causes lysosomal storage disease mucopolysaccharidosis type I which leads to disrupted glycosaminoglycan catabolism.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
---|---|---|---|---|
GMP-Bios-INN-888-1mg | 1mg | 3090 | ||
GMP-Bios-INN-888-10mg | 10mg | Inquiry | ||
GMP-Bios-INN-888-100mg | 100mg | Inquiry | ||
GMP-Bios-INN-888-xmg | ≥100mg | Inquiry | ||
Shipping Cost: | 760.00 | |||
Total: | ||||
Description
Products Name (INN Index) | Pre-Made Lepunafusp Alfa Biosimilar, Fusion Protein targeting TFRC fused with human IDUA (iduronidase, alpha-L-) isoform 1 via a peptidyl linker: Recombinant therapeutic protein targeting CD71/IMD46/T9/TFR/TFR1/TR/TRFR/p90 |
INN Name | Lepunafusp Alfa |
Target | TFRC |
Format | Fusion Protein |
Derivation | Humanized |
Species Reactivity | human |
CH1 Isotype | F(ab')2 - G1 - kappa |
VD LC | F(ab')2 - G1 - kappa |
Highest_Clin_Trial (Jan '20) | |
Est. Status | |
100% SI Structure | |
99% SI Structure | |
95-98% SI Structure | |
Year Proposed | |
Year Recommended | |
Companies | JCR Pharmaceuticals Co., Ltd (Ashiya Japan) |
Conditions Approved | |
Conditions Active | |
Conditions Discontinued | |
Development Tech | 0 |
- GENEMEDI
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- Privacy Policy
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Publications
- Email: [email protected]